Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia

JAMA

Volumn 297, Issue 11, 2007, Pages 1207-1215

  Hijiya, Nobuko ^a,d   Hudson, Melissa M ^a   Lensing, Shelly ^a   Zacher, Margie ^a   Onciu, Mihaela ^a   Behm, Fred G ^a,b   Razzouk, Bassem I ^a,c   Ribeiro, Raul C ^a   Rubnitz, Jeffrey E ^a   Sandlund, John T ^a   Rivera, Gaston K ^a   Evans, William E ^a   Relling, Mary V ^a   Pui, Ching Hon ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Medical Genetics and Neurodevelopmental Center   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BASAL CELL CARCINOMA; BONE MARROW TUMOR; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CHILD; CHRONIC MYELOID LEUKEMIA; EWING SARCOMA; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SOFT TISSUE SARCOMA; UNITED STATES; ACUTE LYMPHOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; SECOND CANCER; SURVIVOR; TIME;

ADOLESCENT; ADULT; CHILD; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASMS, SECOND PRIMARY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS; TIME FACTORS;

EID: 33947496165     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.11.1207     Document Type: Article

References (33)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
2. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
3. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
4. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
5. Schrappe M, Reiter A, Ludwig WD, et al; German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
6. Pui CH, Pei D, Sandlund JT, et al. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:7936-7941.
7. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640-649.
8. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618-629.
9. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330-1336.
10. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257-4264.
11. Löning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95:2770-2775.
12. Simone J, Aur RJ, Hustu HO, Pinkel D. "Total therapy" studies of acute lymphocytic leukemia in children: current results and prospects for cure. Cancer. 1972;30:1488-1494.
13. Pui CH, Dodge RK, Look AT, et al. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St Jude Total Therapy studies VIII, IX, and X. J Clin Oncol. 1991;9:1341-1347.
14. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991;337:61-66.
15. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
16. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
17. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York, NY: John Wiley & Sons; 2002:247-254.
18. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2003 Sub (1973-2001). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2004.
19. Breslow NE, Day NE. Statistical methods in cancer research, volume II: the design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1-406.
20. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
21. Pui CH, Relling MV, Behm FG, et al. L-Asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia. 1995;9:1680-1684.
22. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34-39.
23. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003;101:3862-3867.
24. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol. 1998;16:3761-3767.
25. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
27. Kimball Dalton VM, Gelber RD, Li F, Donnelly MJ, Tarbell NJ, Sallan SE. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:2848-2853.
28. Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005;23:3733-3741.
29. Zwerdling T, Dothage J. Meningiomas in children and adolescents. J Pediatr Hematol Oncol. 2002;24:199-204.
30. Strojan P, Popovic M, Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys. 2000;48:65-73.
31. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:476-483.
32. Edick MJ, Cheng C, Yang W, et al. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer. 2005;42:107-116.
33. Bogni A, Cheng C, Liu W, et al. Genome-wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia. 2006;20:239-246.